Pathological α-synuclein distribution in subjects with coincident Alzheimer’s and Lewy body pathology

Acta Neuropathologica

Volumn 131, Issue 3, 2016, Pages 393-409

  Toledo, Jon B ^a   Gopal, Pallavi ^a   Raible, Kevin ^a   Irwin, David J ^a,b   Brettschneider, Johannes ^a,c   Sedor, Samantha ^a   Waits, Kayla ^a   Boluda, Susana ^a   Grossman, Murray ^b   Van Deerlin, Vivianna M ^a   Lee, Edward B ^a   Arnold, Steven E ^b   Duda, John E ^d   Hurtig, Howard ^b   Lee, Virginia M Y ^a   Adler, Charles H ^e   Beach, Thomas G ^f   Trojanowski, John Q ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF ULM   (Germany)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e MAYO CLINIC   (United States)

^f SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Alzheimer disease; Classification; Dementia with Lewy bodies; Diagnosis; Neuropathology; Parkinson disease

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; SNCA PROTEIN, HUMAN;

AGED; ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; ARTICLE; BRAIN STEM; COHORT ANALYSIS; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPATHOLOGY; OLFACTORY BULB; PARKINSON DISEASE; PRESERVATION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PUTAMEN; SUBSTANTIA NIGRA; CLUSTER ANALYSIS; COMPLICATION; LEWY BODY; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; CLUSTER ANALYSIS; FEMALE; HUMANS; LEWY BODIES; LEWY BODY DISEASE; MALE; PARKINSON DISEASE;

EID: 84958122228     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-015-1526-9     Document Type: Article

References (47)

1. Aarsland D, Ballard CG, Halliday G (2004) Are Parkinson’s disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 17(3):137–145. doi:10.1177/0891988704267470
2. Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J et al (2009) Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 117(6):613–634. doi:10.1007/s00401-009-0538-8
3. Beach TG, Adler CH, Sue LI, Serrano G, Shill HA, Walker DG et al (2015) Arizona study of aging and neurodegenerative disorders and brain and body donation program. Neuropathology 35(4):354–389. doi:10.1111/neup.12189
4. Beach TG, Sue LI, Walker DG, Roher AE, Lue L, Vedders L et al (2008) the sun health research institute brain donation program: description and experience, 1987–2007. Cell Tissue Bank 9(3):229–245. doi:10.1007/s10561-008-9067-2
5. Berg D, Postuma RB, Bloem B, Chan P, Dubois B, Gasser T et al (2014) Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease. Mov Disord 29(4):454–462. doi:10.1002/mds.25844
6. Bohnen NI, Muller ML, Kotagal V, Koeppe RA, Kilbourn MA, Albin RL et al (2010) Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson’s disease. Brain 133(Pt 6):1747–1754. doi:10.1093/brain/awq079
7. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112(4):389–404. doi:10.1007/s00401-006-0127-z
8. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82(4):239–259
9. Braak H, Del Tredici K (2008) Invited article: nervous system pathology in sporadic Parkinson disease. Neurology 70(20):1916–1925. doi:10.1212/01.wnl.0000312279.49272.9f
10. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211 (pii: S0197458002000659)
11. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 318(1):121–134. doi:10.1007/s00441-004-0956-9
12. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A et al (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11(7):909–913. doi:10.1038/ncb1901
13. Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease (1997). Neurobiol Aging 18 (4 Suppl):S1-2
14. Del Tredici K, Braak H (2012) Spinal cord lesions in sporadic Parkinson’s disease. Acta Neuropathol 124(5):643–664. doi:10.1007/s00401-012-1028-y
15. Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM et al (2009) Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet Neurol 8(12):1150–1157
16. Dickson DW, Fujishiro H, Orr C, DelleDonne A, Josephs KA, Frigerio R et al (2009) Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat Disord 15(Suppl 3):S1–S5. doi:10.1016/S1353-8020(09)70769-2
17. Dickson DW, Uchikado H, Fujishiro H, Tsuboi Y (2010) Evidence in favor of braak staging of Parkinson’s disease. Mov Disord 25(Suppl 1):S78–S82. doi:10.1002/mds.22637
18. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22(12):1689–1707. doi:10.1002/mds.21507(quiz 1837)
19. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT et al (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300(5619):636–640. doi:10.1126/science.1082324
20. Goetz C, Emre M, Dubois B (2008) Parkinson’s disease dementia: definitions, guidelines, and research perspectives in diagnosis. Ann Neurol 64(S2):S81–S92
21. Graff-Radford J, Murray ME, Lowe VJ, Boeve BF, Ferman TJ, Przybelski SA et al (2014) Dementia with Lewy bodies: basis of cingulate island sign. Neurology 83(9):801–809. doi:10.1212/WNL.0000000000000734
22. Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B et al (2013) Distinct alpha-synuclein strains differentially promote tau Inclusions in neurons. Cell 154(1):103–117. doi:10.1016/j.cell.2013.05.057
23. Hawkes CH, Del Tredici K, Braak H (2010) A timeline for Parkinson’s disease. Parkinsonism Relat Disord 16(2):79–84. doi:10.1016/j.parkreldis.2009.08.007
24. Heilbronner G, Eisele YS, Langer F, Kaeser SA, Novotny R, Nagarathinam A et al (2013) Seeded strain-like transmission of beta-amyloid morphotypes in APP transgenic mice. EMBO Rep 14(11):1017–1022. doi:10.1038/embor.2013.137
25. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosur Psychiatry 55:181–184. doi:10.1136/jnnp.55.3.181
26. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC et al (2012) National institute on aging-Alzheimer’s association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement 8(1):1–13. doi:10.1016/j.jalz.2011.10.007
27. Hyman BT, Trojanowski JQ (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 56(10):1095–1097
28. Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V et al (2012) Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 72(4):587–598. doi:10.1002/ana.23659
29. Jellinger KA (2009) A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim Biophys Acta 1792(7):730–740. doi:10.1016/j.bbadis.2008.07.006
30. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK (2008) Controversies over the staging of alpha-synuclein pathology in Parkinson’s disease. Acta Neuropathol 116(1):125–128. doi:10.1007/s00401-008-0381-3(author reply 129–131)
31. Leverenz JB, Hamilton R, Tsuang DW, Schantz A, Vavrek D, Larson EB et al (2008) Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathol 18(2):220–224. doi:10.1111/j.1750-3639.2007.00117.x
32. Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF et al (2007) DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68(11):812–819. doi:10.1212/01.wnl.0000256715.13907.d3
33. Lu JX, Qiang W, Yau WM, Schwieters CD, Meredith SC, Tycko R (2013) Molecular structure of beta-amyloid fibrils in Alzheimer’s disease brain tissue. Cell 154(6):1257–1268. doi:10.1016/j.cell.2013.08.035
34. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H et al (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65(12):1863–1872. doi:10.1212/01.wnl.0000187889.17253.b1
35. Mirra SS (1997) The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer’s disease: a commentary. Neurobiol Aging 18(4 Suppl):S91–S94
36. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW et al (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol 123(1):1–11. doi:10.1007/s00401-011-0910-3
37. Olichney JM, Murphy C, Hofstetter CR, Foster K, Hansen LA, Thal LJ et al (2005) Anosmia is very common in the Lewy body variant of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 76(10):1342–1347. doi:10.1136/jnnp.2003.032003
38. Parkkinen L, Pirttila T, Alafuzoff I (2008) Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol 115(4):399–407. doi:10.1007/s00401-008-0346-6
39. Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A et al (2014) Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron. doi:10.1016/j.neuron.2014.04.047
40. Sumikura H, Takao M, Hatsuta H, Ito S, Nakano Y, Uchino A et al (2015) Distribution of alpha-synuclein in the spinal cord and dorsal root ganglia in an autopsy cohort of elderly persons. Acta Neuropathol Commun 3:57. doi:10.1186/s40478-015-0236-9
41. Thal DR, Rub U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58(12):1791–1800
42. Toledo JB, Brettschneider J, Grossman M, Arnold SE, Hu WT, Xie SX et al (2012) CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol 124(1):23–35. doi:10.1007/s00401-012-0983-7
43. Toledo JB, Cairns NJ, Da X, Chen K, Carter D, Fleisher A et al (2013) Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathol Commun 1(1):65. doi:10.1186/2051-5960-1-65
44. Toledo JB, Van Deerlin VM, Lee EB, Suh E, Baek Y, Robinson JL et al (2014) A platform for discovery: the university of pennsylvania integrated neurodegenerative disease biobank. Alzheimers dement 10(4):477–484. doi:10.1016/j.jalz.2013.06.003(e471)
45. Tsuboi Y, Dickson DW (2005) Dementia with Lewy bodies and Parkinson’s disease with dementia: are they different? Parkinsonism Relat Disord 11(Suppl 1):S47–S51. doi:10.1016/j.parkreldis.2004.10.014
46. Wilson RS, Arnold SE, Schneider JA, Boyle PA, Buchman AS, Bennett DA (2009) Olfactory impairment in presymptomatic Alzheimer’s disease. Ann N Y Acad Sci 1170:730–735. doi:10.1111/j.1749-6632.2009.04013.x
47. Zaccai J, Brayne C, McKeith I, Matthews F, Ince PG (2008) Patterns and stages of alpha-synucleinopathy: relevance in a population-based cohort. Neurology 70(13):1042–1048. doi:10.1212/01.wnl.0000306697.48738.b6